CD28 and neoplasm: To overcome these problems, the CAR T cells should be able to disrupt or block the immune checkpoint PD-1/PD-L1, modify to express switch receptor (PD-1-CD28), or modify by addition of inverted cytokine receptor (IL-4R/IL-7)52 to improve the CAR T cell functions within the tumor microenvironment.